Clinical Trials Browser

Phase EARLY_PHASE1 × durvalumab × Dermatologic × Clear all

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Phase EARLY_PHASE1 Withdrawn

Melanoma

NCT03235869 2018-03-15

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Phase EARLY_PHASE1 Withdrawn

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous